Wanda Jimenez
Public Health & General Preventive Medicine · Centralia, WANPI 1306867700
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AstraZeneca at 40.5% of the total. Reporting peaked in 2023 at $613 and has fallen 66.2% since, to $207 in 2024.
Across 75 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$733
- Lilly USA, LLC$320
- Novo Nordisk$261
- Boehringer Ingelheim$206
- Johnson & Johnson$100
- E.r. Squibb & Sons, L.L.C.$59
- plus $128 from 5 others
What the payments were for
- Food & beverage$1,806100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $733 |
| Lilly USA, LLC | 16 | $320 |
| Novo Nordisk | 13 | $261 |
| Boehringer Ingelheim | 10 | $206 |
| Johnson & Johnson | 5 | $100 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Pfizer | 3 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$108
How this compares
Too few public health & general preventive medicine providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 119 | $1,009 |
| Atorvastatin Calcium | 68 | $962 |
| Lisinopril | 50 | $658 |
| Losartan Potassium | 41 | $321 |
| Eszopiclone | 18 | $311 |
| Fluoxetine Hcl | 16 | $283 |
| Omeprazole | 17 | $271 |
| Famotidine | 12 | $248 |
| Metformin Hcl | 16 | $247 |
| Metoprolol Succinate | 19 | $172 |
| Amlodipine Besylate | 23 | $129 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 11 | $114 |
| Meloxicam | 33 | $84 |
| Azithromycin | 12 | $50 |
| Acyclovir | 15 | $33 |
Paid to pharmacies, not to this prescriber.
Other public health & general preventive medicine in Centralia
- Paul StepakLake Forest Park$324K
- Ashley KeaysTacoma$264K
- Hieu HoangTacoma$113
- Lewis RockIssaquah$78
- Bradford WeeksClinton$74
- Mark HillSeattle$67
- Jan MuellerSpokane$17
- Brandon PenixMoses Lake$16
- Evelyn BarrazaTacoma$13
- Caroline TaylorSeattle$13
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.